Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. KAINOS Laboratories's annualizedNet Income for the quarter that ended in Mar. 2026 was 円9 Mil. KAINOS Laboratories's average total tangible assets for the quarter that ended in Mar. 2026 was 円0 Mil. Therefore, KAINOS Laboratories's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 0.10%.
The historical rank and industry rank for KAINOS Laboratories's Return-on-Tangible-Asset or its related term are showing as below:
TSE:4556'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 4.72 Med: 6.55 Max: 7.66
Current: 4.96
During the past 13 years, KAINOS Laboratories's highest Return-on-Tangible-Asset was 7.66%. The lowest was 4.72%. And the median was 6.55%.
TSE:4556's Return-on-Tangible-Asset is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.89
vs TSE:4556: 4.96
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
KAINOS Laboratories Return-on-Tangible-Asset Related Terms
KAINOS Laboratories Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for KAINOS Laboratories's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4556 vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, KAINOS Laboratories's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KAINOS Laboratories Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KAINOS Laboratories's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where KAINOS Laboratories's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 0.10% mean?
KAINOS Laboratories (TSE:4556) has a Return-on-Tangible-Asset of 0.10% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on KAINOS Laboratories and its competitors. This is 98% below median its historical median of 6.55. Over the past decade, KAINOS Laboratories' Return-on-Tangible-Asset has ranged from 4.72 to 7.66.
Is KAINOS Laboratories' Return-on-Tangible-Asset too high?
KAINOS Laboratories' current Return-on-Tangible-Asset of 0.10% is 98% below median its 10-year median of 6.55. Over the past 10 years, this metric has ranged from a low of 4.72 to a high of 7.66. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.89. KAINOS Laboratories' value of 0.10% is 88.8% below this industry median. Overall, KAINOS Laboratories has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does KAINOS Laboratories' Return-on-Tangible-Asset compare to ISRG and BDX?
KAINOS Laboratories' Return-on-Tangible-Asset of 0.10% can be compared against companies in the Medical Devices & Instruments industry. The industry median Return-on-Tangible-Asset is 0.89. KAINOS Laboratories' value of 0.10% is 88.8% below this benchmark. Historically, KAINOS Laboratories' own Return-on-Tangible-Asset has ranged from 4.72 to 7.66 over the past decade. While the company's 10-year median is 6.55 vs. the industry median of 0.89, KAINOS Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.89, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. KAINOS Laboratories's current Return-on-Tangible-Asset of 0.10% is 88.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on KAINOS Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KAINOS Laboratories's current Return-on-Tangible-Asset is 0.10%, which is 98% below median its own 10-year median of 6.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KAINOS Laboratories stock overvalued right now?
KAINOS Laboratories (TSE:4556) has a current Return-on-Tangible-Asset of 0.10%. The stock's GF Value™ is 円1,285.89, compared to a current price of 円2,268.00 — trading 76.4% above its estimated fair value. The current Return-on-Tangible-Asset is 0.10%, which is 98% below median its 10-year median of 6.55 and 88.8% below the Medical Devices & Instruments industry median of 0.89. KAINOS Laboratories' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For KAINOS Laboratories (TSE:4556), the current Return-on-Tangible-Asset is 0.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KAINOS Laboratories (TSE:4556) Overvalued in 2026?
Based on GuruFocus' analysis, KAINOS Laboratories stock appears to be overvalued.
The current stock price of 円2,268.00 is trading 76.4% above its estimated GF Value™ of 円1,285.89.
Key valuation signals for TSE:4556:
Return-on-Tangible-Asset: 0.10% (98% below median its 10-year median of 6.55)
GF Value™: 円1,285.89 vs. price of 円2,268.00 (76.4% above fair value)
Industry Position: 88.8% below the Medical Devices & Instruments median
No single metric tells the full story. See the TSE:4556 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KAINOS Laboratories Inc is focused on the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products. It also manufactures, sells, and exports/imports physicochemical measuring equipment for medical use.
47GF Score
Get the complete analysis for TSE:4556
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4556 has been successfully added to your 
